Synonyms: 15 α-hydroxyestriol | 15 alpha-hydroxyestriol | Drovelis® (EMA); ; estetrol monohydrate + drospirenone | E4 | Lydisilka® (EMA); ; estetrol monohydrate + drospirenone | Nextstellis® (US); estetrol monohydrate + drospirenone
estetrol is an approved drug (EMA & FDA (2021))
Compound class:
Synthetic organic
Comment: Estetrol is a natural estrogen that is produced exclusively during pregnancy by the fetal liver. It is produced synthetically (from a plant source) for medicinal use. Estetrol has tissue selective actions [4-5], with estrogenic activity in the uterus, vagina and endometrium and estrogen antagonist activity in breast tissue.
|
|
No information available. |
Summary of Clinical Use ![]() |
Estetrol (formulated as the monohydrate) is a component of oral contraceptives that also contain drospirenone. The FDA approved drospirenone/estetrol contraceptives in April 2021, and the EMA granted approval a few weeks later in May 2021. As a single agent estetrol has been investigated for efficacy in patients with prostatic neoplasms [2], and is in evaluation to determine its potential in managing menopausal vasomotor symptoms. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT02817841 | E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study | Phase 3 Interventional | Estetra | 3 | |
NCT02817828 | E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study | Phase 3 Interventional | Estetra | 3 | |
NCT03361969 | Evaluation of Effects of Estetrol on Testosterone Suppression and Quality of Life in Prostate Cancer Patients Treated With an LHRH Agonist. | Phase 2 Interventional | Pantarhei Oncology B.V. | ||
NCT04209543 | Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I) | Phase 3 Interventional | Estetra |